BSE filing, NSE: PPLPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Piramal Pharma Ltd: key numbers
- Share price
- ₹230.05
- Market cap
- ₹30,628 Cr
- Revenue (annual)
- ₹8,869 Cr
- Net profit (annual)
- ₹-325.9 Cr
- P/E (TTM)
- -146.7×Sector 46.1×
- Promoter holding
- 34.80%+0.00% QoQ
- FII holding
- 13.65%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Piramal Pharma Ltd
All →Piramal Pharma Investor Presentation: Key Takeaways
Q2FY27 revenue ₹2,617 Cr (+28% YoY), EBITDA margin 14.7% (+372 bps), PAT ₹5 Cr vs loss of ₹99 Cr. FY27 revenue growth outlook raised to 19-20%.
Piramal Pharma Results Update
Piramal Pharma released its Q2/H1 FY27 press release reporting revenue of Rs. 2,617 crore for Q2 and Rs. 4,887 crore for H1, with EBITDA up 72%. The filing also upgrades FY27 revenue growth guidance to 19–20%.
Piramal Pharma Q2 FY27 Results: Turns Profitable, Net Profit ₹5 Cr
Piramal Pharma Ltd reported revenue from operations of ₹2,617 Cr (+28.1% YoY) and net profit of ₹5 Cr for Q2 FY27.
- Key figure
- Net profit ₹5 Cr
Piramal Pharma Other Announcement
The company filed its quarterly shareholding pattern for the period ended September 30, 2026. The report details equity distribution among promoters and public shareholders.
Piramal Pharma Board Meeting Date
Piramal Pharma Limited has scheduled a board meeting on October 27, 2026. The board will consider and approve unaudited financial results for the quarter ended September 30, 2026.
Piramal Pharma Adverse Business Impact
Piramal Pharma announced that its sales and distribution arrangement with Bayer Pharmaceuticals will expire on December 31, 2026, and will not be renewed.
- From
- Bayer Pharmaceuticals Private Limited
Other employee stock options announcements
All →Intellect Design Arena Employee Stock Options
Intellect Design Arena granted 1,83,500 RSUs to 19 associates under its ISOP/RSU 2016 scheme. This ESOP grant carries no transaction value for the event.
- Execution
- Vesting over 1st to 5th year from grant
Edelweiss Financial Services Employee Stock Options
Edelweiss Financial Services allotted 4,42,792 equity shares under its employee stock incentive and appreciation rights plans. No consideration amount is stated, so no event value applies.
Raymond Realty Employee Stock Options
Raymond Realty allotted 1,04,211 equity shares to its ESOP Trust under the RRL ESOP Scheme 2025 following option exercises. Paid-up capital rose to Rs 66.68 Crore.
Strides Pharma Science Employee Stock Options
Strides Pharma allotted 7,500 equity shares to an employee exercising options under the Strides ESOP 2016 Plan. Paid-up capital rises to 92,180,214 shares.
Shaily Engineering Plastics Employee Stock Options
Shaily Engineering Plastics allotted 1,300 equity shares to employees on exercise of ESOPs at Rs. 732 per share under its 2019 plan. Issued paid-up capital rises to 4,59,96,548 shares of Rs. 2 each.
Info Edge (India) Employee Stock Options
Info Edge's employee stock option trust sold 1,439 shares on 26 October 2026 under the ESOP scheme. The disposal reduces the trust's holding to 410,707 shares.